Miniati Mario, Conversano Ciro, Palagini Laura, Buccianelli Beatrice, Fabrini Mariagrazia, Mancino Maricia, Laliscia Concetta, Marazziti Donatella, Paiar Fabiola, Gemignani Angelo
Department of Clinical and Experimental Medicine, University of Pisa, 57 Via Roma, Italy.
Department of Surgical Pathology, Medical, Molecular and Critical Area, University of Pisa, 57 Via Roma, Pisa, Italy.
Clin Neuropsychiatry. 2020 Oct;17(5):300-313. doi: 10.36131/cnfioritieditore20200508.
We reviewed literature on drugs for bipolar disorders (BD), utilized in ovarian cancer (OC).
We adhered to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines in completion of this systematic review.
We identified 73 papers. Thirty-two studies were finally included. BD is rarely diagnosed in OC patients. Limited finding from case reports is available. Drugs used to treat BD (mainly lithium and valproic acid) have been extensively studied in add-on to chemotherapy for treatment-resistant OC cells or in animal models, with promising results in vitro but not in vivo.
The clinical underestimation of BD in OC has leaded to the almost complete absence of evidences for a soundly based clinical guidance in this field. There is a urgent need for a systematic multi-disciplinary approach to OC.
我们回顾了用于卵巢癌（OC）的双相情感障碍（BD）治疗药物的文献。
我们在完成本系统评价时遵循了系统评价和Meta分析的首选报告项目（PRISMA）指南。
我们识别出73篇论文。最终纳入32项研究。OC患者中很少诊断出BD。病例报告的研究结果有限。用于治疗BD的药物（主要是锂盐和丙戊酸）已在难治性OC细胞化疗或动物模型中进行了广泛研究，在体外有前景，但在体内无此效果。
OC中BD的临床低估导致该领域几乎完全缺乏可靠的临床指导证据。迫切需要对OC采取系统的多学科方法。
